Development and internal validation of a prostate health index based nomogram for predicting prostate cancer at extended biopsy

Journal of Urology

Volumn 188, Issue 4, 2012, Pages 1144-1150

  Lughezzani, Giovanni ^a   Lazzeri, Massimo ^a   Larcher, Alessandro ^a   Lista, Giuliana ^a   Scattoni, Vincenzo ^a   Cestari, Andrea ^a   Buffi, Nicoló Maria ^a   Bini, Vittorio ^b   Guazzoni, Giorgio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

biopsy; nomograms; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX BASED NOMOGRAM; VALIDATION PROCESS;

EID: 84866112632     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.06.025     Document Type: Article

References (22)

1. E.A. Heijnsdijk, A. der Kinderen, E.M. Wever Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833
2. F.K. Chun, J.I. Epstein, V. Ficarra Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature Eur Urol 58 2010 851
3. A.J. Vickers, A.M. Cronin, M.J. Roobol The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group Clin Cancer Res 16 2012 4374
4. F.K. Chun, A. de la Taille, H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659
5. G. Lughezzani, A. Briganti, P.I. Karakiewicz Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature Eur Urol 58 2012 687
6. Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2012; 57: 921.
7. B.V. Le, C.R. Griffin, S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2012 1355
8. G. Guazzoni, L. Nava, M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2012 214
9. W.J. Catalona, A.W. Partin, M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
10. T. Rhodes, D.J. Jacobson, M.E. McGree Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men J Urol 187 2012 92
11. G. Guazzoni, M. Lazzeri, L. Nava Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 2012 455
12. E.W. Steyerberg, A.J. Vickers, N.R. Cook Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128
13. C.T. Nguyen, M.W. Kattan How to tell if a new marker improves prediction Eur Urol 60 2011 226
14. A.J. Vickers, E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565
15. A. Semjonow, T. Köpke, E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 47 2010 926
16. V. Scattoni, M. Raber, F. Abdollah Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy Eur Urol 57 2010 1
17. J.I. Epstein, W.C. Allsbrook Jr, M.B. Amin The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228
18. E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
19. C. Stephan, H. Cammann, M. Bender Internal validation of an artificial neural network for prostate biopsy outcome Int J Urol 17 2010 62
20. Auprich M, Haese A, Walz J, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 20120; 58: 727.
21. M.J. Roobol, F.H. Schröder, G.L. van Leenders Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (< 100) Eur Urol 58 2010 893
22. E.W. Steyerberg, F.E. Harrell Jr, G.J. Borsboom Internal validation of predictive models: efficiency of some procedures for logistic regression analysis J Clin Epidemiol 54 2001 774